Search

The decision as to whether to use high-dose iplimumab as an adjuvant treatment for melanoma is difficult and requires excellent communication between physician and patient.

… Wednesday, October 12, 2016 The recent FDA approval of the monoclonal antibody ipilimumab as an adjuvant treatment for melanoma has created an important opportunity for clinicians to weigh the benefits, risks, and limitations of this new treatment option. The FDA’s decision was based on results from

… Monday, August 4, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: MSK Ranked the Best Cancer Center in the Northeast and First in the Nation for Urology Care MSK Ranked the Best Cancer Center in the Northeast and First in the Nation for Urology

Immunotherapy drugs called checkpoint inhibitors have been a game changer for some people with cancer. But for most patients, these drugs have been disappointing. Researchers are trying to figure out why.

… Thursday, December 7, 2017 Summary A new analysis finds that certain genes people are born with may play a critical role in whether or not checkpoint inhibitors will work. For some people with cancer, immunotherapy drugs called checkpoint inhibitors , which take the brakes off the immune system and allow

Immunotherapy drugs called checkpoint inhibitors are effective against many cancers, including kidney cancer. Learn how these drugs are used to treat both early- and late-stage disease.

… Monday, September 12, 2022 In an effort to improve the prognosis (outcomes) for kidney cancer , more patients are receiving immunotherapy , which activates the body’s own immune system to kill cancerous cells. Here, genitourinary medical oncologist Robert Motzer from Memorial Sloan Kettering Cancer Center

The third-annual Crain’s New York Business Notable in Healthcare list celebrates outstanding individuals in the healthcare community within the New York metropolitan area, and honors their professional, civic, and philanthropic achievements.

… Monday, August 10, 2020 Memorial Sloan Kettering (MSK) is proud to announce that Physician-in-Chief and Chief Medical Officer Lisa M. DeAngelis, MD , and Community Outreach Manager Julia Ramirez, MA , are included on the Crain’s New York Business 2020 Notable in Healthcare list. The list celebrates outstanding

The discovery of a molecular process that slows down cell division could provide new understanding about how some cancers develop.

… Tuesday, April 8, 2014 Summary The discovery of a molecular process that slows down cell division could provide new understanding about how some cancers develop. This image, generated in the lab of molecular biologist Prasad Jallepalli , shows a human cell nucleus — a membrane-enclosed compartment within

Scientists have generated a compound that could potentially be used to create a new type of pain medication that may prevent the side effects of currently available painkillers.

… Tuesday, December 13, 2011 Summary Scientists have generated a compound that could potentially be used to create a new type of pain medication that may prevent the side effects of currently available painkillers. A Memorial Sloan Kettering study suggests that in the future, researchers might be able

Twelve students successfully defended their dissertations and received their PhD degrees at Commencement on May 19.

… Monday, May 23, 2016 Twelve students at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences have successfully defended their dissertations. As part of Memorial Sloan Kettering’s 37th annual academic convocation on May 19, the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences

Laboratory research led by MSK and Cold Spring Harbor Laboratory demonstrates the potential for CAR T cells to improve “healthspan” by eliminating senescent cells associated with aging-related diseases.

… Thursday, February 1, 2024 Highlights Laboratory research led by MSK and Cold Spring Harbor Laboratory demonstrates the potential for CAR T cells to improve “healthspan” by eliminating senescent cells associated with aging-related diseases. Not only was the treatment able to improve the metabolic function

MSK medical oncologist Shanu Modi is the lead author of a new paper detailing the results from a phase II trial of a breast cancer drug called trastuzumab deruxtecan or DS-8201a. Results from this study were also presented at the San Antonio Breast Cancer Symposium.

… Wednesday, December 11, 2019 Summary A new study in the New England Journal of Medicine details the results from a phase II trial of a breast cancer drug called trastuzumab deruxtecan or DS-8201a. MSK medical oncologist Shanu Modi is the lead author of the paper, which was also presented at the San Antonio